Your browser doesn't support javascript.
loading
The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma.
Coen, Oliver; Corrie, Pippa; Marshall, Helen; Plummer, Ruth; Ottensmeier, Christian; Hook, Jane; Bell, Sue; Sagoo, Gurdeep S; Meads, David; Bestall, Janine; Velikova, Galina; Gallagher, Ferdia A; Smith, Alexandra; Howard, Helen; Mason, Ellen; Katona, Eszter; Silva, Shobha; Collinson, Michelle; Rodwell, Simon; Danson, Sarah.
Afiliação
  • Coen O; Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Corrie P; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Marshall H; University of Leeds, Leeds, UK.
  • Plummer R; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK.
  • Ottensmeier C; Newcastle University, Newcastle upon Tyne, UK.
  • Hook J; University of Southampton, Southampton, UK.
  • Bell S; Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Sagoo GS; University of Leeds, Leeds, UK.
  • Meads D; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK.
  • Bestall J; University of Leeds, Leeds, UK.
  • Velikova G; University of Leeds, Leeds, UK.
  • Gallagher FA; University of Leeds, Leeds, UK.
  • Smith A; Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Howard H; University of Leeds, Leeds, UK.
  • Mason E; Leeds Institute of Medical Research at St James's University Hospital, Leeds, UK.
  • Katona E; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Silva S; University of Cambridge, Cambridge, UK.
  • Collinson M; University of Leeds, Leeds, UK.
  • Rodwell S; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK.
  • Danson S; University of Leeds, Leeds, UK.
BMC Cancer ; 21(1): 761, 2021 Jul 01.
Article em En | MEDLINE | ID: mdl-34210290
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor de Morte Celular Programada 1 / Imunoterapia / Melanoma / Anticorpos Monoclonais Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor de Morte Celular Programada 1 / Imunoterapia / Melanoma / Anticorpos Monoclonais Idioma: En Ano de publicação: 2021 Tipo de documento: Article